Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013;8(3):e57507.
doi: 10.1371/journal.pone.0057507. Epub 2013 Mar 15.

Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage

Affiliations
Clinical Trial

Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage

Anneloes E Bohte et al. PLoS One. 2013.

Abstract

Long term liver-related complications of type-1 Gaucher disease (GD), a lysosomal storage disorder, include fibrosis and an increased incidence of hepatocellular carcinoma. Splenectomy has been implicated as a risk factor for the development of liver pathology in GD. High ferritin concentrations are a feature of GD and iron storage in Gaucher cells has been described, but iron storage in the liver in relation to liver fibrosis has not been studied. Alternatively, iron storage in GD may be the result of iron supplementation therapy or regular blood transfusions in patients with severe cytopenia. In this pilot study, comprising 14 type-1 GD patients (7 splenectomized, 7 non-splenectomized) and 7 healthy controls, we demonstrate that liver stiffness values, measured by Transient Elastography and MR-Elastography, are significantly higher in splenectomized GD patients when compared with non-splenectomized GD patients (p = 0.03 and p = 0.01, respectively). Liver iron concentration was elevated (>60±30 µmol/g) in 4 GD patients of whom 3 were splenectomized. No relationship was found between liver stiffness and liver iron concentration. HFE gene mutations were more frequent in splenectomized (6/7) than in non-splenectomized (2/7) participants (p = 0.10). Liver disease appeared more advanced in splenectomized than in non-splenectomized patients. We hypothesize a relationship with excessive hepatic iron accumulation in splenectomized patients. We recommend that all splenectomized patients, especially those with evidence of substantial liver fibrosis undergo regular screening for HCC, according to current guidelines.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal’s policy and have the following conflicts: A.E.B., E.M.A., A.J.N., R.S., and J.S. report no potential conflicts of interest. L.V.D. has received travel reimbursements for participation in meetings on lysosomal storage disorders from Genzyme corp. and Protalix Biotherapeutics. C.E.M.H. has received travel reimbursements and speaker/consultancy fees for participation in meetings on lysosomal storage disorders from Genzyme corp., Shire HGT and Protalix Biotherapeutics. All fees are donated to the Gaucher Stichting, a non-profit fund stimulating research on lysosomal storage disorders. P.L.M.J. has received travel reimbursement to various liver conferences unrelated to this work paid from research funds or companies. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Study flow chart.
Figure 2
Figure 2. MRE: selection of region of interest (ROI) in the liver.
ROIs are drawn manually on the elastograms, in the lateral part of the right liver lobe while avoiding liver margins and large hepatic vessels. The mean elasticity value within the ROI in this example (Sx GD patient) is 2.3 kPa (colored bar represents kPa). The corresponding stiffness measured with TE was 7.2 kPa.
Figure 3
Figure 3. Comparison of quantitative imaging results and distribution of HFE mutations.
Solid black horizontal lines represent median values. Presence and distribution of HFE mutations in GD patients are shown in red and green. (A) MR-liver iron concentration (Gandon). Dashed line represents upper limit of normal (60 µmol/g). Median (range) in µmol/g: controls (n = 7) 30 (5–66); non-Sx GD (n = 7) 35 (20–90); Sx GD (n = 7) 35 (10–250). (B) Transient elastography results. Dashed line represents cutoff value for the presence of substantial liver fibrosis (Metavir ≥ F2). Median (range) in kPa: controls (n = 7) 4.9 (3.9–5.9); non-Sx GD (n = 7) 4.8 (3.4–7.2); Sx GD (n = 7) 8.8 (3.5–16.0). (C) MR elastography results. Median (range) in kPa: controls (n = 7) 1.69 (1.53–1.84); non-Sx GD (n = 7) 1.47 (1.32–2.03); Sx GD (n = 4) 2.32 (2.12–2.42).
Figure 4
Figure 4. T2* maps of the liver.
(A) Healthy control with a normal liver T2* value of 26 ms (LIC-Gandon: 20±20 µmol/g). (B) Sx-GD patient with severe iron overload: T2* value in the liver is short: 3.2 ms; the corresponding LIC measured with the Gandon method was high: 250±50 µmol/g.
Figure 5
Figure 5. Correlations between study parameters.
A–C: correlations between MR-LIC and 1/T2* (n = 21), TE (n = 21) and ferritin concentration (n = 14). D–F: correlations between TE and MRE (n = 18), Chitotriosidase activity (n = 14) and ACE (n = 14).

References

    1. Beutler E, Grabowski GA (2001) Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8 ed. New York: McGraw-Hill. 3636.
    1. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. N Engl J Med 291: 989–993. - PubMed
    1. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, et al. (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481–1485. - PubMed
    1. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33–39. - PubMed
    1. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, et al. (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105: 151–156. - PubMed

Publication types

MeSH terms